BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 7693770)

  • 1. Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.
    Czobor P; Volavka J
    J Clin Psychopharmacol; 1993 Oct; 13(5):332-42. PubMed ID: 7693770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.
    Keegan D
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S46-52. PubMed ID: 7533051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological profile of risperidone.
    Ereshefsky L; Lacombe S
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S80-8. PubMed ID: 7504573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risperidone: clinical safety and efficacy in schizophrenia.
    Borison RL; Pathiraja AP; Diamond BI; Meibach RC
    Psychopharmacol Bull; 1992; 28(2):213-8. PubMed ID: 1381102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC; Honer WG
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of risperidone on positive features of schizophrenia.
    McEvoy JP
    J Clin Psychiatry; 1994 May; 55 Suppl():18-21. PubMed ID: 7520904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
    Cesková E; Svestka J
    Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of schizophrenia: a review.
    Sigmundson HK
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S70-5. PubMed ID: 7533053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risperidone in the treatment of schizophrenia.
    Marder SR; Meibach RC
    Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology and treatment of negative symptoms.
    Villeneuve A
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S53-8. PubMed ID: 7533052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.
    Claus A; Bollen J; De Cuyper H; Eneman M; Malfroid M; Peuskens J; Heylen S
    Acta Psychiatr Scand; 1992 Apr; 85(4):295-305. PubMed ID: 1375801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic medication in the treatment of schizophrenia.
    Kane JM
    Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
    Peuskens J
    Br J Psychiatry; 1995 Jun; 166(6):712-26; discussion 727-33. PubMed ID: 7545060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.
    Kerwin RW
    Br J Psychiatry; 1994 Feb; 164(2):141-8. PubMed ID: 7513599
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
    Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative symptoms in schizophrenia: assessment of the effect of risperidone.
    Schooler NR
    J Clin Psychiatry; 1994 May; 55 Suppl():22-8. PubMed ID: 7520905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.